Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Pierre Jordaan"'
Publikováno v:
HTS Teologiese Studies/Theological Studies, Vol 74, Iss 3, Pp e1-e9 (2018)
The structuring of the narrative with characters assigned to fulfil particular roles is often indicative of an author’s possible intent. Thus, characterisation, in a story, is not neutral about its rhetorical intent; it generally reveals cultural v
Externí odkaz:
https://doaj.org/article/bdeada048af245d0a7a4a22c7ef16edf
Autor:
Eugene Coetzer, Pierre Jordaan
Publikováno v:
HTS Teologiese Studies/Theological Studies, Vol 72, Iss 3, Pp e1-e6 (2016)
The events in the introduction to 2 Maccabees (2 Macc 3:1–39) undoubtedly centre round the Jerusalem Temple. It is depicted as world-renowned, holy and just. Many scholars have therefore highlighted the theme of the Temple in 2 Maccabees, introduce
Externí odkaz:
https://doaj.org/article/e00b2496b962437ba5ea2612af24ac16
Autor:
Pierre Jordaan
Publikováno v:
In die Skriflig, Vol 48, Iss 1, Pp e1-e2 (2014)
No abstract available.
Externí odkaz:
https://doaj.org/article/af4dcbb81a094703ac7541ed3ea58a8b
Autor:
Pierre Jordaan
Publikováno v:
HTS Teologiese Studies/Theological Studies, Vol 65, Iss 1, Pp e1-e6 (2009)
When the New Testament is interpreted, directly preceding literature is largely neglected. The dialectical terms, discourse and contra-discourse do not often surface in research on this period. This is especially the case with reference to women. Jes
Externí odkaz:
https://doaj.org/article/d02cdfc2ca0e4439845bb1dc625e362f
Autor:
Sunil Sharma, Pierre Jordaan, Herbert Hurwitz, Shodeinde Coker, Lionel D. Lewis, Juan Pablo Zarate, Ding Wang
Publikováno v:
Cancer Chemotherapy and Pharmacology. 84:383-392
To evaluate the effect of lapatinib on the QTc interval and ECG parameters in patients with advanced solid tumors. This was a multicenter, placebo-controlled study in subjects with advanced solid tumors. Subjects were administered two doses of matchi
Autor:
Andrea Ghetti, Paul E. Miller, Pierre Jordaan, Najah Abi-Gerges, Martin Traebert, Berengere Dumotier, Laszlo Urban
Publikováno v:
Toxicological Sciences
Substantial efforts have been recently committed to develop coronavirus disease-2019 (COVID-19) medications, and Hydroxychloroquine alone or in combination with Azithromycin has been promoted as a repurposed treatment. Although these drugs may increa
Autor:
Carine Kolly, Stefan Viktor Vormfelde, Eric Legangneux, Pierre Jordaan, Gilbert Lefèvre, Ulf Neumann, Nicole Pezous, Mike Ufer
Publikováno v:
Clinical and Translational Science
Umibecestat, an orally active β-secretase inhibitor, reduces the production of amyloid beta-peptide that accumulates in the brain of patients with Alzheimer's disease. The echocardiogram effects of umibecestat, on QTcF (Fridericia-corrected QT), on
Autor:
Pierre Jordaan, Giovanna Muscogiuri, Rosario Pivonello, Michaela Paul, Annamaria Colao, Geoffrey Holder, Anastasia Lesogor, Johannes Eisinger, Severine Sarp
Publikováno v:
Endocrine
Purpose Octreotide (OCT) has been successfully used for treatment of acromegaly and neuroendocrine tumors for more than 30 years. However, long-term safety of OCT has not been documented in placebo-controlled setting. This present analysis pooled saf
Autor:
Andy N. Mead, Pierre Jordaan, Kathryn Chapman, Will S. Redfern, Alessandra Giarola, Jean-Pierre Valentin, Samuel J. Jackson, Lorna Ewart, Philip Jarvis, Hugo M. Vargas, Martin Traebert, Hamid R. Amouzadeh
Publikováno v:
Regulatory Toxicology and Pharmacology. 80:348-357
Central Nervous System (CNS)-related safety concerns are major contributors to delays and failure during the development of new candidate drugs (CDs). CNS-related safety data on 141 small molecule CDs from five pharmaceutical companies were analyzed
Autor:
Pierre Jordaan, Parasar Pal, Zhanna Kobalava, V. S. Moiseev, Margaret F. Prescott, Elena Pavlikova, Surya Ayalasomayajula, Thomas Langenickel, Priya Chandra, Oleg Averkov, Yulia Kotovskaya, Diego Albrecht, Iris Rajman
Publikováno v:
Cardiovascular Therapeutics
SummaryAims Concomitant renin–angiotensin–aldosterone system blockade and natriuretic peptide system enhancement may provide unique therapeutic benefits to patients with heart failure and reduced ejection fraction (HFrEF). This study assessed the